Screening for Mutations in Hereditary Cancer Susceptibility Genes in a Region with High Endogamy in Brazil

Abstract

Introduction Cancer is a multifactorial disease dependent on the influence of genetic and environmental factors. About 10% of cancers are associated with germline mutations, which predispose to a higher risk of developing cancer. Currently, the use of panels that identify susceptibility and/or association genes cancer has been increasingly used, both in clinical practice and in scientific research.
Objective To investigate genetic mutations in patients with a profile for hereditary cancer in individuals from a region of northeast Brazil, where there is a high frequency of endogenous and consanguineous marriages.
Methods A set of 17 genes (BRCA1, BRCA2, APC, TP53, PTEN, RET, VHL, RB1, CDKN2, CDH1, CHEK2, MLH1, MSH2, MSH6, MUTYH, XPA, and XPC) associated with cancer and hereditary syndromes were analyzed. Fifteen patients with a hereditary cancer profile were evaluated.
Results The pathogenic variant found was c.1187G > A (p.Gly396Asp), rs36053993 in the MUTYH gene in a male patient diagnosed with melanoma at the age of 43 years and a family history for this tumor. This gene encodes an important enzyme related to DNA repair and has been associated with other types of cancer, this is the first report of an association with melanoma, the biological plausibility of this association is given once the MUTYH protein is expressed in the skin tissue and is responsible for repairing damage caused, for example, by sun exposure.
Conclusion The results of this study suggest that this mutation may be important for the hereditary predisposition to melanoma, but a broader investigation of this mutation is needed.

Keywords

hereditary cancer / pathogenic variant / multigene panel / endogamy

References

[1] Baranova EE, Bodunova NA, Vorontsova МV. et al.[Hereditary cancer syndromes: a modern paradigm]. Probl Endokrinol (Mosk) 2020; 66(04) 24-34

[2] Foretová L. Hereditary cancer syndromes, their testing and prevention. Cas Lek Cesk 2019; 158(01) 15-21

[3] Katsanis SH, Katsanis N. Molecular genetic testing and the future of clinical genomics. Nat Rev Genet 2013; 14(06) 415-426

[4] Webster P, Dawes JC, Dewchand H. et al. Subclonal mutation selection in mouse lymphomagenesis identifies known cancer loci and suggests novel candidates. Nat Commun2018; 9 (01) 2649 . [published correction appears in Nat Commun 2019 Mar 6;10(1):1167]

[5] Gardner SA, Weymouth KS, Kelly WS. et al. Evaluation of a 27-gene inherited cancer panel across 630 consecutive patients referred for testing in a clinical diagnostic laboratory. Hered Cancer Clin Pract 2018; 16: 1

[6] Price KS, Svenson A, King E, Ready K, Lazarin GA. Inherited cancer in the age of next-generation sequencing. Biol Res Nurs 2018; 20(02) 192-204

[7] Miroševič Š, Klemenc-Ketiš Z, Peterlin B. Family history tools for primary care: A systematic review. Eur J Gen Pract 2022; 28(01) 75-86

[8] Flória-Santos M, Lopes-Júnior LC, Alvarenga LdeM. et al. Self-reported cancer family history is a useful tool for identification of individuals at risk of hereditary cancer predisposition syndrome at primary care centers in middle-income settings: a longitudinal study. Genet Mol Biol 2016; 39(02) 178-183

[9] Machado TM, Bomfim TF, Souza LV. et al. Types of marriages, population structure and genetic disease. J Biosoc Sci2013; 45 (04) 461-470 . [published correction appears in J Biosoc Sci 2013 Jul;45(4):575]

[10] Costa-Motta FM, Bender F, Acosta A. et al. A community-based study of mucopolysaccharidosis type VI in Brazil: the influence of founder effect, endogamy and consanguinity. Hum Hered 2014; 77(1-4): 189-196

[11] Selkirk CG, Vogel KJ, Newlin AC. et al. Cancer genetic testing panels for inherited cancer susceptibility: the clinical experience of a large adult genetics practice. Fam Cancer 2014; 13(04) 527-536

[12] Hermel DJ, McKinnon WC, Wood ME, Greenblatt MS. Multi-gene panel testing for hereditary cancer susceptibility in a rural Familial Cancer Program. Fam Cancer 2017; 16(01) 159-166

[13] Santos HC, Horimoto AV, Tarazona-Santos E. et al; Brazilian EPIGEN Project Consortium. A minimum set of ancestry informative markers for determining admixture proportions in a mixed American population: the Brazilian set. Eur J Hum Genet 2016; 24(05) 725-731

[14] Pereira V, Santangelo R, Børsting C. et al. Evaluation of the precision of ancestry inferences in South American admixed populations. Front Genet 2020; 11: 966

[15] Out AA, Tops CM, Nielsen M. et al. Leiden Open Variation Database of the MUTYH gene. Hum Mutat 2010; 31(11) 1205-1215

[16] Banda DM, Nuñez NN, Burnside MA, Bradshaw KM, David SS. Repair of 8-oxoG:A mismatches by the MUTYH glycosylase: mechanism, metals and medicine. Free Radic Biol Med 2017; 107: 202-215

[17] D'Agostino VG, Minoprio A, Torreri P. et al. Functional analysis of MUTYH mutated proteins associated with familial adenomatous polyposis. DNA Repair (Amst) 2010; 9(06) 700-707

[18] Magrin L, Fanale D, Brando C. et al. MUTYH-associated tumor syndrome: the other face of MAP. Oncogene 2022; 41(18) 2531-2539

[19] Haimov D, Lieberman S, Castellvi-Bel S, Nielsen M, Goldberg Y. Nonmalignant features associated with inherited colorectal cancer syndromes-clues for diagnosis. Cancers (Basel) 2022; 14(03) 628

[20] Vogt S, Jones N, Christian D. et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology2009; 137 (06) 1976-85.e1 , 10

[21] Santonocito C, Paradisi A, Capizzi R. et al. Common genetic variants of MUTYH are not associated with cutaneous malignant melanoma: application of molecular screening by means of high-resolution melting technique in a pilot case-control study. Int J Biol Markers 2011; 26(01) 37-42

[22] Aretz S, Tricarico R, Papi L. et al. MUTYH-associated polyposis (MAP): evidence for the origin of the common European mutations p.Tyr179Cys and p.Gly396Asp by founder events. Eur J Hum Genet 2014; 22(07) 923-929

[23] Pitroski CE, Cossio SL, Koehler-Santos P, Graudenz M, Prolla JC, Ashton-Prolla P. Frequency of the common germline MUTYH mutations p.G396D and p.Y179C in patients diagnosed with colorectal cancer in Southern Brazil. Int J Colorectal Dis 2011; 26(07) 841-846

[24] Torrezan GT, da Silva FC, Santos EM. et al. Mutational spectrum of the APC and MUTYH genes and genotype-phenotype correlations in Brazilian FAP, AFAP, and MAP patients. Orphanet J Rare Dis 2013; 8: 54

[25] Nielsen M, Infante E, Brand R. MUTYH polyposis. In: Adam MP, Mirzaa GM, Pagon RA. et al, eds. GeneReviews®. Seattle (WA): University of Washington,; Seattle; 2012

[26] Hintsala HR, Jokinen E, Haapasaari KM. et al. Nrf2/Keap1 pathway and expression of oxidative stress lesions 8-hydroxy-2′-deoxyguanosine and nitrotyrosine in melanoma. Anticancer Res 2016; 36(04) 1497-1506

[27] Nishisgori C. Current concept of photocarcinogenesis. Photochem Photobiol Sci 2015; 14(09) 1713-1721

[28] Kakehashi A, Ishii N, Okuno T, Fujioka M, Gi M, Wanibuchi H. Enhanced susceptibility of Ogg1 mutant mice to multiorgan carcinogenesis. Int J Mol Sci 2017; 18(08) 1801

[29] Ogbah Z, Puig-Butille JA, Simonetta F. et al Molecular characterization of human cutaneous melanoma-derived cell lines. Anticancer Res 2012; 32(04) 1245-1251

[30] Curia MC, Catalano T, Aceto GM. MUTYH: not just polyposis. World J Clin Oncol 2020; 11(07) 428-449

[31] Dumanski JP, Rasi C, Björklund P. et al. A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors. Endocr Relat Cancer 2017; 24(08) 427-443

[32] Uhlén M, Fagerberg L, Hallström BM. et al. Proteomics. Tissue-based map of the human proteome. Science 2015; 347(6220) 1260419

[33] Oka S, Nakabeppu Y. DNA glycosylase encoded by MUTYH functions as a molecular switch for programmed cell death under oxidative stress to suppress tumorigenesis. Cancer Sci 2011; 102(04) 677-682

[34] Oka S, Leon J, Tsuchimoto D, Sakumi K, Nakabeppu Y. MUTYH, an adenine DNA glycosylase, mediates p53 tumor suppression via PARP-dependent cell death. Oncogenesis2014; 3 (10) e121. [published correction appears in Oncogenesis 2015 Feb 23;4:e142]

[35] Ponti G, Losi L, Pellacani G. et al. Malignant melanoma in patients with hereditary nonpolyposis colorectal cancer. Br J Dermatol 2008; 159(01) 162-168

[36] Mazzei F, Viel A, Bignami M. Role of MUTYH in human cancer. Mutat Res2013; 743-744: 33-43

[37] Moretti D, Del Bello B, Allavena G, Corti A, Signorini C, Maellaro E. Calpain-3 impairs cell proliferation and stimulates oxidative stress-mediated cell death in melanoma cells. PLoS One 2015; 10(02) e0117258

[38] Win AK, Reece JC, Buchanan DD. et al. Risk of colorectal cancer for people with a mutation in both a MUTYH and a DNA mismatch repair gene. Fam Cancer 2015; 14(04) 575-583

[39] Rennert G, Lejbkowicz F, Cohen I, Pinchev M, Rennert HS, Barnett-Griness O. MutYH mutation carriers have increased breast cancer risk. Cancer 2012; 118(08) 1989-1993

[40] Toussi A, Mans N, Welborn J, Kiuru M. Germline mutations predisposing to melanoma. J Cutan Pathol 2020; 47(07) 606-616

RIGHTS & PERMISSIONS

2023 Global Medical Genetics